Bli medlem
Bli medlem

Du är här

2016-10-27

Galapagos NV: Galapagos to present progress in CF programs at NACFC 2016

Nine posters and four oral presentations reflect clinical progress toward
triple combination therapy

Mechelen, Belgium; 27 October 2016 -
Galapagos NV (Euronext&NASDAQ: GLPG) will present the following plenary
presentations and posters at the
North American Cystic Fibrosis Conference (NACFC) in Orlando this week:

Pleneray presentations

Thursday 27 Oct. Oral session W02: CFTR 2016, 9:45 am ET
Bertrand Kleizen
(Utrecht University) - "The novel potentiator GLPG1837 modulates CFTR through
different mode of action than ivacaftor (Kalydeco®)."

Saturday 29 Oct . Oral session W22: Rare CFTR mutations&How to fix them, 10:30
am ET
Yi Cheng
(RFUMS) - "The C.1766+1G->A splice site mutation causes Exon 13 skipping
resulting in multiple defects in CFTR structure and function."

Saturday 29 Oct. Oral session: W29: Emerging Strategies for Correcting the
Basic CFTR Gene Defect, 10:30 am ET
Ashvani Sing
h (AbbVie) - "Discovery and Characterization of ABBV/GLPG2222, a novel first
generation corrector."
Mutyam Venkateshwar
(UAB) - "Novel correctors and potentiators augment efficacy of translational
readthrough in CFTR nonsense mutations."

Poster presentations

Poster 4 - The novel potentiator GLPG1837 modulates CFTR through different
mode of action than ivacaftor (Kalydeco)

Galapagos reports on the investigation of mode of action of Kalydeco and
GLPG1837 and determines when and where these potentiators work on the newly
synthesized CFTR protein.

Poster 13 - The C.1766+1G->
A splice site mutation causes Exon 13 skipping resulting in multiple
defects in CFTR structure and function

RFUMS, Galapagos and AbbVie report the characterization of the C.1766+1G->A
CFTR splice site mutation, showing it results in multiple defects including
protein biogenesis, maturation and channel function.

Poster 19 - Measuring potentiator activity using organoids

Galapagos and AbbVie present the development of assays using patient-derived
organoids and the data obtained using GLPG1837 across assays.

Poster 20 - Characterization of a novel potentiator series for treating cystic
fibrosis

Galapagos and AbbVie describe the identification of a second generation
potentiator series with very good channel opening activity. From this series,
GLPG2451 was identified and is currently in Phase 1 clinical trials.

Poster 23 - Characterization of novel CFTR potentiators

University of Missouri-Columbia, Galapagos and Abbvie characterize potentiator
GLPG1837 by patch clamp.

Poster 189 - Novel correctors and potentiators augment efficacy of
translational readthrough in CFTR nonsense mutations

University of Alabama, Galapagos and AbbVie report the evaluation of
combination(s) of novel correctors, a potentiator and Read Through agents to
enhance efficacy in CFTR cells expressing a variety of nonsense mutations, to
levels likely to be therapeutic for CF.

Poster 192 - Discovery and characterization of ABBV/GLPG2222, a novel first
generation CFTR corrector

Galapagos and AbbVie report the identification andin vitro
characterization of ABBV/GLPG2222, a novel, potent and orally bioavailable
corrector currently in clinical trials that exhibitsin vitro
cellular improvements over the existing correctors in the clinic.

Poster 252 - Safety, tolerability and pharmacokinetics of a novel CFTR
corrector molecule GLPG2222 in healthy volunteers

Galapagos and AbbVie report the results for the First-in-Human study with
GLPG2222. Safety and tolerability were evaluated in oral single (up to 800
mg) and multiple ascending doses (up to 600 mg q.d. for 14 days) in healthy
subjects. The pharmacokinetic profile showed GLPG2222 to be rapidly absorbed
with an elimination half-life of 12 hours, steady-state after 2 days, and
minimal accumulation. GLPG2222 was found to be generally well tolerated

Poster 253 - GLPG1837 in subjects with cystic fibrosis and the S1251N
mutation: results from a phase2a study (SAPHIRA 2)

Novel potentiator GLPG1837 was administered in two doses, each for two weeks,
to 7 patients with the S1251N mutation in a small, exploratory, open-label,
multi-center study. Purpose of the study was to confirmin vitro
observations with clinical responses. The doses selected for SAPHIRA 2 were at
the low end of the efficacious dose range, whereby the exposures of GLPG1837
in plasma ranged around the lower target concentration for efficacy. Even at
these low doses, CFTR activity was observed through decreases in sweat
chloride and increases in FEV1, with changes in absolute percent predicted
FEV1 from baseline in Kalydeco naïve patients being in line with those
published for Kalydeco in S1251N subjects after two weeks treatment. A 7-day
pre-treatment washout of Kalydeco impacted lung function slightly (-3%), and
during treatment with GLPG1837, no further decline was observed in Kalydeco
experienced patients. GLPG1837 was generally well tolerated in CF patients
when dosed up to 4 weeks.

All posters will be made available on the Galapagos website,www.glpg.com,
shortly following the presentation sessions. On Friday 28 October at 14.00
CET, there is a webcast and call on our Q3 Results. Our CSO Piet Wigerinck
will be available to answer scientific questions.

The North American Cystic Fibrosis Conference is sponsored by the Cystic
Fibrosis Foundation:www.cff.org

For more information on cystic fibrosis:http://www.glpg.com/rd-cystic-fibrosis

About Galapagos

Galapagos (Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises a maturing pipeline of Phase 3,
Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis,
inflammation, fibrosis, osteoarthritis and other indications. We have
discovered and developed filgotinib: in collaboration with Gilead we aim to
bring this JAK1-selective inhibitor for inflammatory indications to patients
all over the world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's lives. The
Galapagos group, including fee-for-service subsidiary Fidelta, has
approximately 480 employees, operating from its Mechelen, Belgium
headquarters and facilities in The Netherlands, France, and Croatia. More
information atwww.glpg.com.

Contacts

------------------------------------------------
| Investors: Media: |
| Elizabeth Goodwin Evelyn Fox |
| VP IR&Corporate Director Communications |
| |
|Communications |
|+1 781 460 1784 +31 6 53 591 999 |
| |
| communications@glpg.com |
| Paul van der Horst |
|Director IR&Business |
|Development |
|+31 6 53 725 199 |
| ir@glpg.com |
------------------------------------------------
Forward-looking statements
This release may contain forward-looking statements, including statements
regarding the potential activity of in the Company's product candidates for
cystic fibrosis. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos,
or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in
differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements (including that data from Galapagos' ongoing
clinical research programs in cystic fibrosis may not support registration or
further development of its correctors and potentiators due to safety,
efficacy or other reasons), Galapagos' reliance on collaborations with third
parties (including the performance by AbbVie under the Galapagos-AbbVie
Collaboration Agreement), and estimating the commercial potential of its
product candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities and
Exchange Commission (SEC) filings and reports, including in Galapagos' most
recent annual report on Form 20-F filed with the SEC and subsequent filings
and reports filed by Galapagos with the SEC. Given these uncertainties, the
reader is advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the date of
publication of this document. Galapagos expressly disclaims any obligation
to update any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based or that may
affect the likelihood that actual results will differ from those set forth in
the forward-looking statements, unless specifically required by law or
regulation.

Galapagos at NACFC 2016
http://hugin.info/133350/R/2051975/767909.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.